Evidence map›Paper›PMID 30316805›Full record

Trial reportExperimental hematology2019

Interleukin-18 plays a dispensable role in murine and likely also human bone marrow failure.

Zhijie Wu, Valentina Giudice, Jichun Chen, Wanling Sun, Zenghua Lin, Keyvan Keyvanfar, Nidhi Talasani, Sachiko Kajigaya, Xingmin Feng, Neal S Young

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Experimental hematology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Prolonged haematologic toxicity in CAR-T-cell therapy: A review.Journal of cellular and molecular medicine · 2023
    Review
  7. Article
  8. Pyroptosis-Induced Inflammation and Tissue Damage.Journal of molecular biology · 2022
    Review
  9. Article
  10. Review
  11. Article
  12. [Advances in the pathogenesis of aplastic anaemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Zhijie WuHematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Valentina GiudiceHematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Jichun ChenHematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Wanling SunHematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Zenghua LinHematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Keyvan KeyvanfarHematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Nidhi TalasaniHematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Sachiko KajigayaHematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Xingmin FengHematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA. Electronic address: fengx2@nhlbi.nih.gov.
Neal S YoungHematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
National Institutes of Health · US

Funding

Pathogenesis And Treatment Of Aplastic AnemiaZIAHL002315 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI YOUNG, NEAL S · 2009 to 2025
$60.1M
PATHOGENESIS AND TREATMENT OF APLASTIC ANEMIAZ01HL002315 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI YOUNG, NEAL S · 1985 to 2008
$9.5M
Intramural NIH HHS Z01 HL002315
6 · The paper itself

Abstract

Interleukin-18 (IL-18), also known as interferon-gamma (IFN-γ)-inducing factor, is involved in Th1 responses and regulation of immunity. Accumulating evidence implicates IL-18 in autoimmune diseases, but little is known of its role in acquired aplastic anemia (AA), the immune-mediated destruction of bone marrow (BM) hematopoietic stem and progenitor cells (HSPCs). IL-18 protein levels were significantly elevated in sera of severe AA (SAA) patients, including both responders and nonresponders assayed before treatment, and decreased after treatment. IL-18 receptor (IL-18R) was expressed on HSPCs. Co-culture of human BM CD34

Indexed as

AdolescentAdultAgedAged, 80 and overAnemia, AplasticAnimalsChildChild, PreschoolDisease Models, AnimalFemaleHematopoietic Stem CellsHumansInterferon-gammaInterleukin-18Interleukin-18 Receptor alpha SubunitInterleukin-6IFNG protein, humanIFNG protein, mouseIL18R1 protein, humanIl18r1 protein, mouseIL6 protein, humanInterferon-gammaInterleukin-18Interleukin-18 Receptor alpha SubunitInterleukin-6interleukin-6, mouseTumor Necrosis Factor-alpha

Identifiers

PMID30316805
PMCPMC6309608
OpenAlexW2897927509

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.